Lipoprotein(a) and peripheral atherosclerosis in older adults

Atherosclerosis

Volumn 122, Issue 1, 1996, Pages 11-19

  Sutton Tyrrell, Kim ^a   Evans, Rhobert W ^a   Meilahn, Elaine ^a   Alcorn, Hope G ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Atherosclerosis; Carotid stenosis; Lipoprotein(a); Peripheral vascular disease

Indexed keywords

LIPOPROTEIN A;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL;

EID: 0029964374     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05734-X     Document Type: Article

References (53)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963;59:369.
2. Scanu A, Fless G. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990;85:1709.
3. Marcovina SM, Albers JJ, Jacobs DR, Perkins LL, Lewis CE, Howard BV, Savage P. Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans. Arteriosclerosis Thromb 1993;13:1037.
4. Levitsky LL, Scanu AM, Gould SH. Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care 1991;14:283.
5. Sandholzer C, Hallman DM, Saha N, Sigurdson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G. Effects of the apolipoprotein (a) size polymorphism on the lipoprotein (a) concentration in seven ethnic groups. Hum Genet 1991;86:607.
6. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children: Bogalusa Heart Study. Circulation 1991;84:160.
7. Hoefler G., et al. Lipoprotein Lp(a): A risk factor for myocardial infarction. Atherosclerosis 1988;18:398.
8. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kantz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758.
9. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc 1986;256:2540.
10. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of Systolic Hypertension in the Elderly (SHEP). J Am Med Assoc 1991;265:3255.
11. Hoff H, Beck G, Skibinski C. et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988;77:1238.
12. Hearn J, Donohue B, Ba'albaki H, Douglas J, King S, Lembo N, Roubin G, Sgoutas D. Usefulness of serum Lipoprotein(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736.
13. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K. Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942.
14. Jurgens G, Koltringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology 1987;37:513.
15. Durrington P, Ishola M, Hunt E. et al. Apolipoproteins(a), A1, and B and mental history in men with early onset ischaemic heart disease. Lancet 1988;1070.
16. Olofsson B, Dahlen O, Nilsson T. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary heart disease. Eur Heart J 1989;1:77.
17. Haffner S, Moss S, Klein B, Klein R. Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism 1992;41:194.
18. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population of middle aged men. Br Med J 1990;301:1248.
19. Schaefer E, Lamon-Fava S, Jenner J, McNamara J, Ordovas J, Davis E, Abolafia J, Lippel K, Levy R. Lipoprotein(a) levels and risk of coronary heart disease in men: The Lipid Research Clinics Coronary Primary Prevention Trial. J Am Med Assoc 1994;271:999.
20. Jauhaiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59.
21. Ridker P, Hennekens C, Stampfer M. A prospective study of lipoprotein(a) and the risk of myocardial infarction. J Am Med Assoc 1993;270:2195.
22. Petrovitch H, Byington R, Bailey G, et al. Systolic Hypertension in the Elderly Program (SHEP): baseline characteristics of the randomized sample, II: screening and recruitment. Hypertension, 1991;17(suppl II): 16.
23. Black HR, Curb JD, Pressel S, Probstfield JL, Stamler J, eds. Systolic Hypertension in the Elderly Program (SHEP): baseline characteristics of the randomized sample. Hypertension 1991;17(suppl II):1.
24. Blackshear W, Phillips DJ, Chikos PM, Harley JD, Thiele BL, Strandness DE. Carotid artery velocity patterns in normal and stenotic vessels. Stroke 1980;11:67.
25. Keagy BA, Pharr WF, Thomas D, Bowes DE. A quantitative method for the evaluation of spectral analysis patterns in carotid artery stenosis. Ultrasound Med Biol 1982;8:625.
26. Ouriel K, McDonnell A, Metz C, Zarins C. A critical evaluation of stress testing in the diagnosis of peripheral disease. Surgery 1982;91:686.
27. Spencer MP, Reid JM. Quantitation of carotid stenosis with continuous wave (C-W) Doppler ultrasound. Stroke 1979;10:326.
28. Sutton-Tyrrell K, Wolfson SK, Thompson T, Kelsey SF. Measurement variability in duplex scan assessment of carotid atherosclerosis. Stroke 1992;23:215.
29. Prineas RI, Harland WR, Janzon L, et al. Recommendations for use of non-invasive methods to detect atherosclerotic peripheral disease in population studies. Circulation 1982;65:1561A.
30. Criqui MH, Fronek A, Klauber MR, et al. The sensitivity, specificity and predictive value of traditional clinical evaluation of peripheral disease: results from non-invasive testing in a denned population. Circulation 1985;71:516.
31. Simons L, Friedlander Y, Simons J, McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis 1993;99:87.
32. Fless GM, Snyder ML. Polymorphic forms of Lp(a) with different structural and functional properties: cold-induced self-association and binding to fibrin and lysine-Sepharose. Chem Phys Lipids 1994;67-68:69.
33. Albers J, Marcovina S. Standardization of Lp(a) measurements. Chem Phys Lipids 1994;67/68:257.
34. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470.
35. Warnick GR, Albers JJ. A comprehensive evaluation of heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19:65.
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
37. Kahn HA and Sempos CT. Relative risk and odds ratio. In: MacMahon, (ed). Statistical Methods in Epidemiology, ch 3. New York: Oxford University Press, 1989:44-71.
38. Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, Heiss G. Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arteriosclerosis Thromb 1993;13:826.
39. Jovicic A, Ivanisevic V, lanovic I. Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993;98:59.
40. Sutton-Tyrrell K, Wolfson SK, Kuller LH. Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke 1994;25:44.
41. Scanu AM. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988;112:1045.
42. Loscalzo J. Lipoprotein(a): A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672.
43. Walton KW, Hitchens J, Magani HN, Khan M. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis 1974;20:323.
44. Walton KW. Distribution of lipoproteins in arteries and tissues as determined by immunohistological and radioactive tracer methods. In: Peeters H, (ed). Protides of the Biological Fluids, 19th colloq, 1971. Oxford: Pergamon Press, 1972;225-226.
45. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579.
46. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989;9:593.
47. Haijar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303.
48. McLean JW, Tomlinson JE, Kuang WJ. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132.
49. Miles LA, Fless GM, Levin EF, Scanu AM, Plow EF. A potential basis for the thrombolytic risks associated with lipoprotein(a). Nature 1989;339:301.
50. Ezratty A, Simon DI, Loscalgo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993;32:4628.
51. Rath M, Pauling L. Hypothesis: Lipoprotein(a) is a surrogate for ascorbate. Proc Natl Acad Sci USA 1990;87:6204.
52. Rath M, Pauling L. Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion of the hypoascorbic guinea pig. Proc Natl Acad Sci USA 1990;87:9388.
53. Brown MS, Goldstein JL. Teaching old dogmas new tricks. Nature 1987;330:113.